Mina Rizeik

Check of data completeness; Case triage; Import of XML-HL7 files in the Client safety database; Check for duplicates; Inclusion of ICSRs (initial and fu) from clinical studies and post marketing received from clients in the pharmacovigilance database; MedDRA coding; Collaborate with clinical operations teams to develop robust safety monitoring plans for clinical trials, ensuring the protection of patient welfare; Reviewe medical literature for relevant case reports involving company products, staying informed about potential new or emerging risks associated with their use.

Being a pharmacist means contributing to the protection of people's health through information, patient awareness, and collaboration with other healthcare professionals. To do this, one must know not only the medications and pharmacological interactions but also all health products, including dietary supplements, medical devices, and cosmetics, as well as measuring certain fundamental parameters for the prevention of certain diseases.

As a Clinical Research Coordinator, I managed phase II, phase III, and observational studies in the oncology field. I also participated in the entry of clinical data (completing and managing CRFs) following Good Clinical Practices. As a Phase I Pharmacist, I managed the Phase I medications, participated in monitoring and audits, updated ongoing clinical studies, and contributed to the drafting of the study protocol.

In my experience as a researcher, I participated in the European project Recognized as 'Eye as a Window of the Brain' with the dual aim of evaluating potential common mechanisms between diabetes and Alzheimer’s disease and finding early biomarkers to enable timely diagnosis of Alzheimer’s. I used retinal imaging tools (OCT and Fluorescein Angiography) and conducted behavioral tests for the in vivo evaluation of mouse models, as well as immunofluorescence for ex vivo assessment.